Ligand to Participate in Two Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:

• Deutsche Bank 40th Annual Health Care Conference in Boston. Presentation on Wednesday, May 6, 2015, at 9:20 a.m. Eastern time (6:20 a.m. Pacific time). Matt Foehr, President and COO, will present for Ligand.
• Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas. Presentation on Tuesday, May 12, 2015, at 6:40 p.m. Eastern time (3:40 p.m. Pacific time). John Higgins, CEO, will present for Ligand.

A live webcast of the presentations will be available on Ligand’s website at www.ligand.com. A replay of the presentations will be archived on the website for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world’s leading pharmaceutical companies including Novartis, Amgen Inc., Merck, Pfizer, Baxter International and Eli Lilly & Co. Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.

Ligand Pharmaceuticals Incorporated
John Higgins, CEO
(858) 550-7500
[email protected]
@Ligand_LGND
or
LHA
Bruce Voss
(310) 691-7100
[email protected]
@LHA_IR_PR

Source: Ligand Pharmaceuticals Incorporated

You May Also Be Interested In

• Leerink Starts Ligand Pharma (LGND) at Outperform
• Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO
• Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition